2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the provided data.

**0. Summary Report**

*   **Return Comparison:** MRK has significantly underperformed the S&P 500 (VOO) with a much lower cumulative return.
*   **Moving Averages:** Recent price is slightly above 20-day SMA, indicating a potential for continued short term upward trend.
*   **Indicators:** The Market Risk Indicator suggests a medium investment recommendation. The stock is currently oversold based on the RSI.
*   **News:** Recent news is generally positive, highlighted by analyst upgrades and positive trial results.
*   **Analyst Opinion:** Analysts have a consensus "Buy" rating with an average target price significantly higher than the current price.
*   **Earnings:** Recent earnings and revenue figures are strong.
*   **Financials:** Revenue is strong, with consistently high profit margins and increasing Equity, with positive ROE.

**1. Return Comparison: MRK vs. S&P 500 (VOO)**

*   **Ticker:** MRK (Merck & Co Inc)
*   **Overview:** Merck is a global pharmaceutical company focused on developing and manufacturing medicines and vaccines.
*   **MRK Cumulative Return:** 19.83%
*   **VOO Cumulative Return:** 99.09%
*   **Divergence:**
    *   Absolute: -82.8%
    *   Relative: 16.8%

**Analysis:** MRK has significantly underperformed the S&P 500. The relative divergence of 16.8% suggests that the current divergence is near the lower end of its historical range, indicating potential for possible trend change.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
|------------|---------|--------|--------|------|--------|
| 2015-2017  | 1.0%    | 68.5%  | -28.0% | 0.0  | 134.1  |
| 2016-2018  | 36.0%   | 69.8%  | 21.0%  | -0.0 | 182.1  |
| 2017-2019  | 40.0%   | 69.8%  | 18.0%  | 0.3  | 216.8  |
| 2018-2020  | 16.0%   | 79.6%  | -8.0%  | 0.3  | 195.0  |
| 2019-2021  | 2.0%    | 79.6%  | -44.0% | 0.7  | 191.4  |
| 2020-2022  | 15.0%   | 79.6%  | 16.0%  | 0.7  | 277.1  |
| 2021-2023  | 33.0%   | 79.6%  | 31.0%  | 0.3  | 272.3  |
| 2022-2024  | -4.0%   | 79.6%  | -25.0% | 0.2  | 248.5  |
| 2023-2025  | -29.0%  | 71.5%  | -93.0% | 1.7  | 251.5  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows fluctuating growth over the periods, with recent periods showing negative growth.
*   **MDD (Maximum Drawdown):**  The high MDD figures indicate significant potential losses during these periods.
*   **Alpha:** The inconsistent alpha values highlight periods of both outperformance and underperformance relative to the market. The most recent period shows very significant underperformance.
*   **Beta:** The beta values show the stock's volatility compared to the market.  A beta consistently around 0.3 except for the most recent period indicates that MRK has generally been less volatile than the market, but is now much more volatile.
*   **Cap(B) (Market Capitalization in Billions):** Shows the company's size.

**2. Recent Stock Price Fluctuations**

*   **Close:** 100.69
*   **Last Market:** Price: 100.69, Previous Close: 99.18, Change: 1.52
*   **5-day SMA:** 99.74
*   **20-day SMA:** 100.2535
*   **60-day SMA:** 91.4192

**Analysis:** The stock price closed slightly above its 20-day SMA. This could indicate short-term positive momentum. The 5-day SMA is lower than 20-day, indicating that this is recent upward movement. The 60-day SMA is significantly lower, meaning that the stock is still recovering from previous lower prices.

**3. Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 39.11 (Oversold)
*   **PPO:** -0.603
*   **Hybrid Signal:** cash\_0% Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 3.1 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -52.3% (Expected excess return compared to S&P 500 if invested long-term from this point)

**Analysis:**

*   The MRI suggests a moderate level of risk, making it suitable for investors with a medium risk tolerance.
*   The RSI indicates that the stock is currently oversold, which can sometimes signal a potential buying opportunity.
*   The PPO is negative, suggesting the stock is in a downtrend.
*   The hybrid signal suggests reinvesting most available cash, based on the MRI score.
*   The negative expected return is a significant concern, suggesting underperformance compared to the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events**

*   **Positive:** Analyst Upgrade (MarketBeat, GuruFocus), Positive Keytruda-Padcev Trial Results (ts2.tech), Stock Trading Up (Yahoo Finance), BMO Capital Upgrades and Raises Price Target to $130 (GuruFocus).
*   **Negative/Mixed:**  Stock Down 3% (Quiver Quantitative).

**Analysis:** The news sentiment is mixed, with a lean towards positive. Analyst upgrades and positive trial data are bullish signals. However, the report of a recent price decrease indicates some volatility or concern in the market.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.97 (~Buy)
*   **Number of Opinions:** 26
*   **Target Price:**
    *   Average: 110.04
    *   High: 139.00
    *   Low: 83.00

**Analysis:** The analyst consensus is strongly positive, with a "Buy" rating. The average target price suggests significant upside potential from the current price.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-11-05 | 2.32 | 17.28 B$      |
| 2025-08-05 | 1.76 | 15.81 B$      |
| 2025-05-02 | 2.01 | 15.53 B$      |
| 2024-11-06 | 1.25 | 16.66 B$      |
| 2025-11-05 | 1.25 | 16.66 B$      |

**Analysis:** Earnings per share (EPS) and revenue have been generally increasing over the past several quarters. This indicates strong financial performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%         |
| 2025-06-30   | $15.81B    | 77.50%         |
| 2025-03-31   | $15.53B    | 77.98%         |
| 2024-12-31   | $15.62B    | 75.50%         |
| 2024-09-30   | $16.66B    | 75.51%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $51.85B   | 11.16% |
| 2025-06-30   | $48.99B   | 9.04%  |
| 2025-03-31   | $48.34B   | 10.51% |
| 2024-12-31   | $46.31B   | 8.08%  |
| 2024-09-30   | $44.50B   | 7.09%  |

**Analysis:**

*   **Revenue:** The company has shown consistent revenue generation over the past few quarters, and recent revenue is increasing.
*   **Profit Margin:** Very high and stable profit margins indicate strong operational efficiency and pricing power.
*   **Equity:** Increasing equity suggests a strengthening financial position.
*   **ROE (Return on Equity):**  The ROE is consistently positive and increasing, demonstrating the company's ability to generate profits from shareholders' investments.

**7. Comprehensive Analysis**

Merck & Co. (MRK) presents a mixed investment picture.

*   **Negatives:** The stock has significantly underperformed the S&P 500. The expected return of -52.3% is a major red flag. While the RSI suggests the stock is oversold, the negative PPO reinforces the idea that the price has been trending downward and may continue to.
*   **Positives:** Recent news is generally positive, with analyst upgrades and positive trial results. The analyst consensus is a "Buy" with a considerable upside based on target prices. The company demonstrates strong financial performance, with increasing revenue and EPS. Profit margins are exceptionally high, and equity is increasing, leading to improved ROE.

**Conclusion:**

MRK's recent underperformance relative to the S\&P 500 and the negative expected return are significant concerns. However, strong financial performance, positive recent news, and bullish analyst sentiment provide counterpoints. The medium MRI indicates a moderate risk profile. Further investigation is warranted to determine the root cause of the underperformance and the likelihood of a turnaround. A key aspect will be assessing the impact of recent positive news and analyst ratings on the stock's future performance. The oversold RSI, recent short term price increase and positive trial data might mean that this is the bottom of MRK's trend.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.